)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Jubilant Pharmova
Jubilant Pharmova (530019) investor relations material
Jubilant Pharmova Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 26/27 earnings summary10 Aug, 2026
Executive summary
Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved by the Board and subjected to limited review by statutory auditors.
Both standalone and consolidated results were prepared in accordance with Ind AS and SEBI regulations.
Financial highlights
Consolidated revenue from operations for Q1 FY27 was ₹22,211 million, up from ₹18,789 million in Q1 FY26 and ₹22,722 million in Q4 FY26.
Consolidated profit for the period was ₹564 million, compared to ₹1,193 million in Q4 FY26 and ₹1,025 million in Q1 FY26.
Standalone revenue from operations for Q1 FY27 was ₹671 million, compared to ₹703 million in Q4 FY26 and ₹595 million in Q1 FY26.
Standalone profit for the period was ₹74 million, compared to ₹571 million in Q4 FY26 and ₹57 million in Q1 FY26.
Outlook and guidance
No explicit forward-looking guidance provided, but results were reviewed and approved by the Board, indicating ongoing operational focus.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Jubilant Pharmova
- Record FY20 profitability came with COVID-19 disruption and deferred capex.530019
Q4 19/20 - Pharmaceuticals drove record revenue, while the IFC settlement weighed on reported profit.530019Q4 18/19
- Products growth offset weaker Services as FY11 results absorbed demerger and H1N1 comparisons.530019Q4 10/11
- Record FY17 results, injectables momentum and lower leverage offset significant operating risks.530019Q4 16/17
- EBITDA climbed 76% as pharma growth drove a strong FY16 earnings recovery.530019Q4 15/16
- Record FY18 growth, led by specialty pharma and ingredients, alongside debt reduction and Triad integration.530019Q4 17/18
- Flat revenue masked weaker earnings; radiopharma growth and FY16 recovery plans offered offsets.530019Q4 14/15
- Revenue grew 12%, while exceptional costs and sterile-compliance issues weighed on profit.530019Q4 13/14
- FY10 growth accelerated, led by pharma and life sciences, with debt reduced and expansion planned.530019Q4 09/10
- Revenue grew 25%, EBITDA 57%; exceptional charges cut reported PAT to ₹146 million.530019Q4 11/12
Next Jubilant Pharmova earnings date
Q2 26/2716 Nov, 2026
Jubilant Pharmova
Next Jubilant Pharmova earnings date
Q2 26/2716 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Jubilant Pharmova Limited is a pharmaceutical company engaged in the development, manufacturing, and supply of specialty pharmaceuticals and contract research services. The company operates across segments including contract development and manufacturing (CDMO), radiopharma, allergy therapy products, and proprietary pharmaceuticals. It also provides drug discovery and development services to global pharmaceutical and biotechnology companies. The company is headquartered in Noida, India, and its shares are listed on the BSE.